COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Fondazione IRCCS Istituto Nazionale dei Tumori · Vanderbilt University Medical Center · +49 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
623
total citations
- FWCI
- 46.35
- Percentile
- 100%
- References
- 28
Citations per year
Authors
49- MCMarina Chiara GarassinoCorresponding
Fondazione IRCCS Istituto Nazionale dei Tumori
- JGJennifer G. Whisenant
Vanderbilt University Medical Center
- LHLi‐Ching Huang
Vanderbilt University Medical Center
- ATAnnalisa Trama
Fondazione IRCCS Istituto Nazionale dei Tumori
- VTValter Torri
Mario Negri Institute for Pharmacological Research
Topics & keywords
Topics
Keywords
- Medicine
- Lung cancer
- Internal medicine
- Cohort
- Cancer registry
- Pneumonia
- Odds ratio
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- BBayer
- GGlaxoSmithKline
- MMerck
- NNovartis
- SSanofi
- SUStanford University
- GSGilead Sciences
- SPSpectrum Pharmaceuticals
- CCelgene
- AAbbVie
- TPTakeda Pharmaceutical Company
- EREuropean Respiratory Society
- RPRegeneron Pharmaceuticals
- EExelixis
- LLLes Laboratories Pierre Fabre
- COClovis Oncology
- RIRoche Italia
- IIncyte
- GTG1 Therapeutics
- INInstitut National de la Santé et de la Recherche Médicale
- EEisai
- OPOtsuka Pharmaceutical
- PPharmaMar
- GGrifols
- SSamsung
- BSBristol-Myers Squibb Canada
- MSMerck Sharp and Dohme
- FMFoundation Medicine